Mirvie

Mirvie has developed a proprietary RNA-based blood test that can predict serious pregnancy complications such as preeclampsia and severe fetal growth restriction months before they occur. Their Encompass test demonstrated high predictive accuracy for preterm preeclampsia in large-scale studies, identifying 9 out of 10 pregnancies at risk. The technology leverages machine learning to analyze tens of thousands of cell-free RNA messages from mother, fetus, and placenta to provide actionable insights for personalized prenatal care. In a study of over 5,000 pregnancies, the platform predicted 60% of severe FGR cases months in advance—a significant improvement over current standards. A landmark study enrolled over 10,000 participants to further validate these findings.